By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Bâtiment Villejuif Bio Park
1 mail du Professeur Georges Mathé
  Villejuif  94800   France
Phone: 33-1-43-90-19-20 Fax: n/a



Company News
THERAVECTYS Taps Alain Clergeot as New CEO 12/21/2015 6:12:42 AM
THERAVECTYS Appoints Dr. Jean-Pierre Bizzari To Board Of Directors 9/25/2015 11:00:41 AM
THERAVECTYS To Present Detailed Phase I/II Results From The First-Ever Lentiviral-Vector Based Therapeutic Vaccine Trial At The 2015 Towards An HIV Cure Symposium 7/20/2015 10:36:22 AM
THERAVECTYS Attends The American Society Of Gene & Cell Therapy & Presents A Progress Update On Its R&D And Production Activities 5/13/2015 11:33:50 AM
THERAVECTYS Upped Hiring Almost Five-Fold in 2014, As Biotech Booms, Says HR Head 4/22/2015 12:56:26 PM
THERAVECTYS Secures Exclusive Access To A Synthetic Humanized Nanobody Library From Institut Curie And Strengthens Its Proprietary Immunotherapeutic Platform 4/14/2015 9:00:38 AM
THERAVECTYS to Hire Up to 25 As New French Manufacturing Plant Receives Approval 3/26/2015 4:52:52 PM
THERAVECTYS Granted Authorization By The French National Agency For Medicines To Produce Lentiviral Vectors For Clinical Use And CAR-T Cell Therapies Under GMP Standards 3/23/2015 10:21:07 AM
Delaware Court Finds That THERAVECTYS Is Reasonably Likely To Succeed On The Merits Of Its Tortious Interference Claim Against Immune Design Corporation (IMDZ) 3/11/2015 11:22:57 AM
THERAVECTYS Obtains Orphan Drug Designation From European Medicines Agency For Its Lentiviral Vector-Based Therapeutic Vaccine Against Adult T-Cell Leukemia And Lymphoma 2/5/2015 9:43:53 AM